Phase I and pharmacokinetic study of HGS-ETR2, a fully human agonistic monoclonal antibody to TRAIL-R2, in patients with advanced solid malignancies.

被引：0
|
作者：
Attard, G
Plummer, RE
De Bono, JS
Bale, C
Fong, P
Barrett, M
Fox, NL
Howard, T
Ullrich, S
Calvert, H
机构：
[1] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[2] No Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England
[3] Human Genome Sci, Rockville, MD USA
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9060S / 9060S
页数：1
相关论文
共 50 条
  • [41] Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies
    Chu, Quincy S. C.
    Schwartz, Garry
    de Bono, Johann
    Smith, Deborah A.
    Koch, Kevin M.
    Versola, Melissa J.
    Pandite, Lini
    Arya, Nikita
    Curtright, Jan
    Fleming, Ronald A.
    Ho, Peter T. C.
    Rowinsky, Eric K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (24) : 3753 - 3758
  • [42] A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI
    Sikic, B. I.
    Wakelee, H. A.
    von Mehren, M.
    Lewis, N.
    Calvert, A. H.
    Plummer, E. R.
    Fox, N. L.
    Howard, T.
    Jones, S. F.
    Burris, H. A., III
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors
    Papadopoulos, Kyriakos P.
    Kelley, Robin Kate
    Tolcher, Anthony W.
    Razak, Albiruni R. Abdul
    Van Loon, Katherine
    Patnaik, Amita
    Bedard, Philippe L.
    Alfaro, Ariceli A.
    Beeram, Muralidhar
    Adriaens, Lieve
    Brownstein, Carrie M.
    Lowy, Israel
    Kostic, Ana
    Trail, Pamela A.
    Gao, Bo
    DiCioccio, A. Thomas
    Siu, Lillian L.
    CLINICAL CANCER RESEARCH, 2016, 22 (06) : 1348 - 1355
  • [44] Phase I dose escalation, pharmacokinetic, and biomarker study of imatinib mesylate plus capecitabine in advanced solid tumor malignancies.
    Favaro, J. P.
    Petros, W.
    Hong, T.
    Fernando, N.
    Bendell, J. C.
    Gockerman, J. P.
    George, D. J.
    Williams-Truax, R.
    Nixon, A.
    Yu, D.
    Hurwitz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 144S - 144S
  • [45] A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI.
    Sikic, Branimir I.
    Wakelee, Heather A.
    Von Mehren, Margaret
    Lewis, Nancy L.
    Plummer, E. Ruth
    Calvert, A. Hilary
    Fox, Norma Lynn
    Kumm, Elizabeth A.
    Jones, Suzanne F.
    Burris, Howard A.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3454S - 3455S
  • [46] A phase I combination study of irofulven (IROF) and gemcitabine (GEM) in patients (pts) with advanced solid malignancies.
    O'Bryant, CL
    Gore, L
    Long, M
    Gustafson, D
    Eppers, S
    Basche, M
    Rothenberg, M
    Weems, G
    Shah, A
    Herdrich, L
    Eckhardt, SG
    Berlin, J
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9119S - 9120S
  • [47] A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies.
    Owonikoko, Taofeek Kunle
    Harvey, R. Donald
    Kauh, John S.
    Lewis, Colleen Margaret
    Hossain, Mohammed S.
    Akintayo, Adebowale O.
    Merriewether, A. Rene
    Chen, Zhengjia
    Hawk, Natalyn Nicole
    Saba, Nabil F.
    Harris, Wayne
    Shin, Dong Moon
    El-Rayes, Bassel F.
    Huang, Chunzi
    Lonial, Sagar
    Lawson, David H.
    Khuri, Fadlo Raja
    Waller, Edmund K.
    Ramalingam, Suresh S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] A phase I Study of ecteinascidin 743(E) and capecitabine (C) in patients (pts) with advanced solid malignancies.
    Holden, SN
    Rivera, E
    Basche, M
    Gore, L
    Raj, SKS
    O'Bryant, CL
    Grolnic, S
    Hunt, J
    Brillhart, B
    Van de Velde, H
    Roberts, D
    Rodgers, J
    Eckhardt, SG
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6080S - 6080S
  • [49] A phase I clinical and pharmacokinetic study of ipifarnib in combination with docetaxel in patients with advanced solid malignancies
    Awada, Ahmad
    Zhang, Steven
    Gil, Thierry
    de Valeriola, Dominique
    Lalami, Yassine
    De Porre, Peter
    Piccart-Gebhart, Martine J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (05) : 991 - 1003
  • [50] A First-in-human Phase I Study to Evaluate the Fully Human Monoclonal Antibody OMP-59R5 (anti-Notch2/3) Administered Intravenously to Patients with Advanced Solid Tumors
    Smith, D. C.
    Chugh, R.
    Patnaik, A.
    Papadopoulos, K.
    Chambers, G.
    Thorpe, V.
    Xu, L.
    Kapoun, A. M.
    Dupont, J.
    Tolcher, A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 11 - 12
12345